Singapore-based Vela Diagnostics has secured the CE Mark for its next-generation sequencing (NGS) based Sentosa SQ HCV Genotyping Assay for in-vitro diagnostic hepatitis C treatment.

The assay is approved for viral genotyping of 1, 2, 3, 4, 5, and 6, and subtypes 1a and 1b in patients diagnosed with hepatitis C Virus infection from human plasma or serum sample.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It covers clinically relevant regions of NS3, NS5A and NS5B and has exhibited 100% clinical sensitivity and 99.39% clinical genotyping accuracy.

The assay operates on the highly automated Sentosa NGS workflow, which results in the delivery of a series of functions such as RNA extraction, library construction, template preparation, sequencing, data analysis and generation. These are then available in reports into both pathology and quality control (QC).

The QC reports offer complete QC information, while the one on pathology states the detected variants in the patient, and provides automated reporting.

See Also:

Sentosa NGS workflow promotes clarity in sample traceability, with seamless laboratory information system (LIS) integration and connectivity.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Hepatitis C is a chronic medical condition where the virus is based in the liver in 85% of those infected.

Genotyping information is necessary prior to a therapy as it is selected on the basis of a specific genotype and is relevant for the management of HCV infected patients.

Vela Diagnostics provides automated platforms to support both NGS and PCR workflows, which share the Sentosa SX 101 automatic pipetting system, resulting in enhanced efficiency and flexibility.